Phaseline

Companies › Design Therapeutics

Design Therapeutics: clinical trials, targets and expected readouts

2 active drug programs in 2 registered trials: 1 Phase 2, 1 Phase 1; Ophthalmology, Neurology; next expected readout Dec 2026.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
DT-168
Unclear mechanism - likely targeting corneal endothelial cell dysfunction or dystrophy pro
–Phase 2Fuchs Endothelial Corneal DystrophyDec 2027
DT-216P2
Unclear - code-named compound for Friedreich's ataxia
–Phase 1Friedreich AtaxiaDec 2026

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT06874010DT-216P2Phase 1Friedreich AtaxiaNeurologyDec 2026
NCT07024693DT-168Phase 2Fuchs Endothelial Corneal DystrophyOphthalmologyDec 2027

From the company's SEC filings

Cash and short-term investments of $209m on 2026-09-30; operating cash outflow about $64m a year; runway about 39 months at that burn, to Jan 2030; 1 of 1 coming phase 2-3 readouts fall inside that runway

Press releases filed as 8-K in the last year:

Specialist investors

Held by 9 of the 39 life-science funds Phaseline follows through their 13F filings. Who holds what.

Targets

No annotated target.

Companies with the same targets

–

Companies built like this

Bright Minds Biosciences Bausch & Lomb PolyActiva Ashvattha Therapeutics Belite Bio

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.